A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetic and Food Effect of BCI-838; and, An Open-Label Minidose Bioavailability Study to Compare Several BCI-632 Pro-drug Candidates in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2014

At a glance

  • Drugs BCI 838 (Primary) ; BCI 1038; BCI 1206; BCI 1283
  • Indications Major depressive disorder
  • Focus Adverse reactions
  • Sponsors BrainCells
  • Most Recent Events

    • 06 Mar 2012 Actual initiation date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 06 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01546051).
    • 29 Feb 2012 The study was completed, according to a BrainCells media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top